摘要
Abstract
Objective:to evaluate the adr in joint promote the feasibility of red blood cels to the recent advances in the treatment of auxin ischemic stroke.Methods: selected during March 2015 to July 2015 in our hospital for treatment of 100 cases of progression in patients with ischemic stroke as the research object, according to the adr mentioned treatment wil be divided into groups and salvia miltiorrhiza polyphenols acid salt, each 50 cases in each group, with the adr group adopts the adr in jointly promote red blood cel auxin treatment, salvia miltiorrhiza polyphenols acid salt group was treated with salvia miltiorrhiza polyphenols acid salt, and after the treatment, compared two groups of patients before and after treatment of neural function defect scale, before and after treatment serum levels of EPQ and the incidence of adverse reactions. Results:by contrast, found in the adr group patients before and after treatment serum levels of EPQ than salvia miltiorrhiza phenolic acid salt group, before and after treatment of nerve function defect grade and lower incidence of adversereactions salvia miltiorrhiza phenolic acid salt group, two groups have significant difference (P < 0.05), with statistical significance.Conclusion:according to the advances in the treatment of edaravone in combination to promote red blood cel auxin ischemic stroke is higher, the feasibility of the desirable good treatment effect, less incidence of adverse reactions, worthy of clinical popularization and application.关键词
依达拉奉/促红细胞生长素/进展性缺血性卒中/可行性评估Key words
Edaravone/EPO/Progress in ischemic stroke/The feasibility evaluation
